{"id":587496,"date":"2022-02-21T18:24:01","date_gmt":"2022-02-21T18:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=587496"},"modified":"2022-02-21T18:24:01","modified_gmt":"2022-02-21T18:24:01","slug":"choroidal-neovascularization-pipeline-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-roche-regeneron-and-adverum","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/choroidal-neovascularization-pipeline-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-roche-regeneron-and-adverum_587496.html","title":{"rendered":"Choroidal Neovascularization Pipeline: Comprehensive Assessment into the Ongoing Clinical Trials, Treatment Algorithm, Novel and Emerging Therapies | Key Companies &#8211; Roche, Regeneron, and Adverum"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Choroidal Neovascularization Pipeline: Comprehensive Assessment into the Ongoing Clinical Trials, Treatment Algorithm, Novel and Emerging Therapies | Key Companies - Roche, Regeneron, and Adverum\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Choroidal Neovascularization Pipeline: Comprehensive Assessment into the Ongoing Clinical Trials, Treatment Algorithm, Novel and Emerging Therapies | Key Companies - Roche, Regeneron, and Adverum\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cChoroidal Neovascularization Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Choroidal Neovascularization Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Choroidal Neovascularization Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Choroidal Neovascularization Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/60e88cd0e67a6882f2dfd142114d6c62.jpg\" alt=\"Choroidal Neovascularization Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/choroidal-neovascularization-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Choroidal Neovascularization Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Choroidal Neovascularization<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the <strong>Choroidal Neovascularization Treatment<\/strong>.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Choroidal Neovascularization key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Choroidal Neovascularization Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Choroidal Neovascularization market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/choroidal-neovascularization-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/choroidal-neovascularization-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Choroidal Neovascularization Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The dynamics of the Choroidal Neovascularization market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Choroidal Neovascularization Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regeneron Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Adverum Biotechnologies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Iconic Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Choroidal Neovascularization Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lucentis&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eylea<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ADVM-022<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ICON-1<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/choroidal-neovascularization-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/choroidal-neovascularization-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Choroidal Neovascularization&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Choroidal Neovascularization Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Choroidal Neovascularization &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Choroidal Neovascularization Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Choroidal Neovascularization Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Choroidal Neovascularization Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Choroidal Neovascularization Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Choroidal Neovascularization Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Choroidal Neovascularization Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Choroidal Neovascularization Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Choroidal Neovascularization Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Choroidal Neovascularization Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/choroidal-neovascularization-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/choroidal-neovascularization-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Healthcare Report by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cancer-related-fatigue-market\">Cancer Related Fatigue Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Fatigue is one of the common problems and debilitating symptoms in cancer patients. It is observed that a majority of patients experience some level of fatigue during their course of treatment. However, to overcome the Cancer Related Fatigue, globally several key companies are working in the therapeutics domain.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=choroidal-neovascularization-pipeline-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-roche-regeneron-and-adverum\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=choroidal-neovascularization-pipeline-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-roche-regeneron-and-adverum\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cChoroidal Neovascularization Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Choroidal Neovascularization Market. The Choroidal Neovascularization Pipeline report embraces in-depth commercial and clinical assessment of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/choroidal-neovascularization-pipeline-comprehensive-assessment-into-the-ongoing-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-roche-regeneron-and-adverum_587496.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-587496","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/587496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=587496"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/587496\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=587496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=587496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=587496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}